lol some issues eh?
do you understand the difficulty of achieving this given no MOA and the variability of bone marrow derived MSC?
your rosy outlook flies in the face of 2 CRLS.
I would love for MSB to achieve however MSCs will continue to be a huge efficacy and consistency issue for other indications.
Paediatric steroid resistant aGVhD ain't a big market and an approval is more totemic however doctors will need to be satisfied themselves that the standard of care therapy does not provide better outcomes other than less side effects.
Back pain trial, page-18
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.67 |
Change
-0.115(6.46%) |
Mkt cap ! $2.032B | |||
| Open | High | Low | Value | Volume |
| $1.72 | $1.74 | $1.65 | $3.406M | 2.007M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 1013 | $1.67 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.67 | 320 | 1 |
View Market Depth
| Last trade - 10.41am 15/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |